IDEAYA Biosciences Quarterly Cash Flow Statement
NASDAQ: IDYAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
IDEAYA Biosciences free cash flow
In the quarter ended Jun 30, 2026, IDEAYA Biosciences generated -$88.2 million of operating cash flow and spent $866,000 on capital expenditures. That left free cash flow of -$89.1 million, a free-cash-flow margin of -1005.7% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
IDEAYA Biosciences cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -112.45M | -98.54M | -83.27M | 119.24M | -77.49M | -72.18M | -130.31M | -51.82M | -52.77M | -39.57M | -33.95M | -27.44M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | -1799.07% |
| Depreciation & Amortization | 688.00K | 688.00K | 721.00K | 661.00K | 718.00K | 600.00K | 572.00K | 577.00K | 622.00K | 616.00K | 629.00K | 640.00K |
| Stock-Based Compensation | 16.66M | 14.54M | 11.79M | 12.22M | 11.87M | 10.24M | 9.48M | 9.21M | 9.73M | 6.31M | 4.80M | 5.30M |
| Change in Working Capital | 7.84M | 5.49M | -6.42M | 1.38M | -864.00K | 758.00K | 1.26M | -4.91M | 9.35M | -3.58M | 6.27M | -7.43M |
| Operating Cash Flow | -88.21M | -75.17M | -90.50M | 142.21M | -62.47M | -60.34M | -121.66M | -49.23M | -32.88M | -43.81M | -23.75M | -30.17M |
| Capital Expenditures | -866.00K | -967.00K | -333.00K | -42.00K | -663.00K | -1.33M | -1.10M | -457.00K | -973.00K | -1.32M | -838.00K | -603.00K |
| Investing Cash Flow | -155.93M | 118.95M | -97.53M | 41.77M | 45.92M | 79.82M | -197.11M | -20.04M | 68.56M | -353.97M | -111.94M | 51.35M |
| Financing Cash Flow | 359.21M | 1.18M | 2.13M | 301.00K | 1.21M | 26.14M | 2.75M | 286.50M | 39.18M | 349.11M | 140.89M | 27.83M |
| Net Change in Cash | 115.07M | 44.96M | -185.89M | 184.28M | -15.35M | 45.62M | -316.01M | 217.23M | 74.86M | -48.67M | 5.20M | 49.01M |
| Free Cash Flow | -89.08M | -76.14M | -90.83M | 142.17M | -63.14M | -61.67M | -122.76M | -49.69M | -33.85M | -45.14M | -24.59M | -30.78M |
This table shows 12 quarterly periods of IDEAYA Biosciences's cash flow statement, from Q2 2026 back to Q3 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow IDYA's reporting calendar. What is a cash flow statement?